Related Experiment Video
Updated: Jun 13, 2026
07:58
Formulation and Characterization of Bioactive Agent Containing Nanodisks
Published on: March 17, 2023
[Liposomal-amphotericin B efficacy and safety].
Yukihiro Hamada1, Toshiaki Komatsu, Yoshinori Seto
1Department of Pharmacy, Kitasato University Hospital.
Summary
Liposomal amphotericin B (L-AMB) effectively treats fungal infections, but requires careful monitoring. Patients on L-AMB may experience decreased serum potassium, particularly around days 5-6, necessitating regular monitoring for safe and effective use.
Area of Science:
- Mycology
- Pharmacology
- Clinical Medicine
Context:
- Liposomal amphotericin B (L-AMB) is a key antifungal agent used in Japan since 2006.
- Limited post-marketing data exists on L-AMB's real-world efficacy and safety.
- This study addresses the need for updated information on L-AMB's clinical status.
Purpose:
- To retrospectively evaluate the efficacy and safety of L-AMB in treating fungal infections.
- To identify potential adverse events associated with L-AMB treatment.
- To analyze the relationship between L-AMB dosage and specific adverse events.
Summary:
- The study reviewed 25 patients treated with L-AMB for fungal infections.
- 16 patients (64%) demonstrated clinical improvement.
- Adverse events included elevated creatinine (1 patient) and decreased serum potassium (6 patients), with a dose-dependent relationship observed for hypokalemia.
Impact:
- L-AMB demonstrates significant efficacy in treating fungal infections.
- Hypokalemia is a notable adverse effect, often occurring around days 5-6 of treatment.
- Routine serum potassium monitoring is crucial for safe L-AMB administration.
Related Concept Videos
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).